{"disease":{"id":"colitis-ulcerative","name":"colitis ulcerative"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04567628","title":"Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":7873,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02727959","title":"Inflammatory Bowel Disease in South Eastern Norway","phase":"","overall_status":"COMPLETED","enrollment_count":2286,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03662919","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2274,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05796245","title":"A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":2207,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06246123","title":"A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants","phase":"","overall_status":"RECRUITING","enrollment_count":2040,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT03532932","title":"A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice","phase":"","overall_status":"COMPLETED","enrollment_count":1990,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03090139","title":"Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets","phase":"","overall_status":"COMPLETED","enrollment_count":1731,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06651281","title":"Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04372108","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","phase":"","overall_status":"RECRUITING","enrollment_count":1056,"lead_sponsor_name":"Janssen Scientific Affairs, LLC","has_results":false},{"nct_id":"NCT04089514","title":"A Real-world Study of Imraldi® Use","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT02407236","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":961,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT06873711","title":"The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis","phase":"","overall_status":"COMPLETED","enrollment_count":926,"lead_sponsor_name":"Second Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06961435","title":"An Analysis of the Relationship Between the Genetic Polymorphisms of Plasminogen Activator Inhibitor-1 and Ulcerative Colitis in Chinese Patients","phase":"","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Second Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT07196748","title":"A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":882,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02497469","title":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":771,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02620046","title":"A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":746,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04799496","title":"A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis","phase":"","overall_status":"COMPLETED","enrollment_count":688,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04597905","title":"Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":686,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04259138","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":672,"lead_sponsor_name":"Alimentiv Inc.","has_results":false},{"nct_id":"NCT05242484","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":577,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04872491","title":"A Study of Vedolizumab in Adults in Real-World Practice","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06338930","title":"Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":456,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT05528510","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":418,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT03710486","title":"A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants","phase":"","overall_status":"COMPLETED","enrollment_count":409,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT00151944","title":"Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT07102368","title":"A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Janssen-Cilag G.m.b.H","has_results":false},{"nct_id":"NCT02611830","title":"Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":383,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02229344","title":"Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Janssen Korea, Ltd., Korea","has_results":false},{"nct_id":"NCT06294925","title":"A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis","phase":"","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02165215","title":"A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":359,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04873700","title":"A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)","phase":"","overall_status":"COMPLETED","enrollment_count":335,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02743806","title":"Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":331,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07222189","title":"A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":325,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02770599","title":"Improving the Health Care in Inflammatory Bowel Disease.","phase":"","overall_status":"UNKNOWN","enrollment_count":304,"lead_sponsor_name":"University Hospital of North Norway","has_results":false},{"nct_id":"NCT02678052","title":"OTIS Vedolizumab Pregnancy Exposure Registry","phase":"","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06398626","title":"An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03441893","title":"Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT05499130","title":"A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT00503243","title":"Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT03029143","title":"Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":278,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03412682","title":"To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"Ferring Pharmaceuticals","has_results":false},{"nct_id":"NCT06049017","title":"A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05668013","title":"A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":247,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D LLC","has_results":false},{"nct_id":"NCT03488030","title":"A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)","phase":"","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03844932","title":"A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"Sublimity Therapeutics Holdco Limited","has_results":false},{"nct_id":"NCT03173144","title":"Chronic Inflammatory Disease, Lifestyle and Treatment Response","phase":"","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT07242248","title":"A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)","phase":"","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT01959282","title":"A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03662542","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}